Factores de riesgo de la enfermedad por hígado graso no alcohólico en poblaciones de Latinoamérica: situación actual y perspectivas

Oliveira, Cláudia Pinto Marques Souza de; Cotrim, Helma Pinchemel; Arrese, Marco

doi:10.1002/cld.837

Cited by 9 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1,2 En 2020, en el mundo había alrededor de 1500 millones de personas con algún tipo de hepatopatía crónica (incidencia de 20.7/100 000 habitantes). 3 En 2021, la enfermedad hepática en México fue la séptima causa de muerte. 4 Esta enfermedad tiene alta prevalencia e implica un elevado consumo de recursos para su atención.…”

Section: Antecedentesunclassified

Correlation of liver fibrosis quantification by morphometry using HepaScan with the analysis of liver biopsies. A pilot study

Alemán-García¹,

García-García²,

Durán-Padilla³

et al. 2023

GMM

View full text Add to dashboard Cite

PF) mediante HepaScan. Material y métodos: Estudio piloto observacional, analítico, transversal, prospectivo y prolectivo en el que se analizaron cortes histopatológicos de hígado de 29 personas fallecidas por alguna hepatopatía y 22 personas fallecidas por otras causas (controles). El PF se calculó con HepaScan en fotografías digitales de cortes histológicos teñidos con la técnica Masson, comparándolo con el diagnóstico de tres patólogos expertos. Resultados: Fueron analizadas 401 imágenes del grupo con hepatopatía y 250 del grupo de control. La concordancia interobservador tuvo un índice kappa de 0.329. Entre los grupos de clasificación histopatológica existieron diferencias estadísticas en el PF (p = 0.0001). La capacidad predictiva de HepaScan con base en el área bajo la curva característica operativa del receptor fue de 0.983, 0.812 y 0.895 para fibrosis leve, moderada y severa, respectivamente. Conclusiones: HepaScan mostró muy buen desempeño para evaluar el PF en cortes histológicos, por lo que puede coadyuvar al diagnóstico patológico cualitativo.

show abstract

Section: Antecedentesunclassified

Correlation of liver fibrosis quantification by morphometry using HepaScan with the analysis of liver biopsies. A pilot study

Alemán-García¹,

García-García²,

Durán-Padilla³

et al. 2023

GMM

View full text Add to dashboard Cite

show abstract

“…El HGNA es una entidad compleja, que se ve afectada por factores ambientales interrelacionados y por una predisposición genética. 7 Se evidencia mayor prevalencia y mayor estadio de HGNA a mayor edad. 8 El sexo masculino es un factor de riesgo y la prevalencia en hombres es dos veces mayor que en mujeres.…”

Section: Factores De Riesgounclassified

“…36 Desde una perspectiva clínica, los factores asociados con progresión de fibrosis y cirrosis en general son el aumento de peso y la obesidad, la presencia de DM2 y la severidad de la fibrosis hepática al momento de diagnóstico. 1,4,7,8 Historia natural La historia natural del HGNA es todavía incierta y son pocos los estudios realizados con buen diseño para determinar su pronóstico a largo plazo. Los estudios más antiguos al respecto, [37][38][39][40][41][42] que ya reportaban que la obesidad y la DM2 eran factores de riesgo para fibrosis, se llevaron a cabo con un número limitado de pacientes, altamente seleccionados y con un tiempo de seguimiento corto.…”

Section: Mecanismos De Fibrosis Hepáticaunclassified

Hígado graso no alcohólico: certezas e incertidumbres de una epidemia silenciosa

Ballerga¹,

Curia²,

Cusi³

2020

Acta gastroenterol. latinoam.

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is the most frequent chronic liver disease, with an estimated prevalence of 20-30% in the general population and increased to 60-80% in risk groups. It encompasses the spectrum of diseases ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), which can progress to variable degrees of fibrosis, cirrhosis and all its complications. It is associated with cardiovascular, neoplasm and liver mortality, requiring a multidisciplinary approach. A change in the entity name has recently been suggested and a group of experts has proposed calling it Metabolic (dysfunction) Associated Fatty Liver Disease (MAFLD). This name has not yet been accepted and has generated significant controversy. Due to the increase in its prevalence, nonalcoholic fatty liver disease has become a relevant health problem that requires specific actions for its detection, diagnosis, monitoring and treatment. Identifying patients at risk of progressing to more severe forms is essential but not too easy. Patients with nonalcoholic steatohepatitis should be identified; mainly those with fibrosis, the most important characteristic associated with mortality. The main treatment for all stages of the disease consists of lifestyle interventions and aggressive correction of comorbidities. Other therapies, such as treatment with pioglitazone or GLP-1RA, should be selected and used in patients with nonalcoholic steatohepatitis who are at higher risk of progression of liver and cardiovascular disease, like obese and type 2 diabetic patients.

show abstract

“…Based on obesity rates, it is estimated that NAFLD prevalence is 26% in Mexico and 15%-20% in Central America. [10][11][12] There is a bidirectional association between NAFLD and the components of MetS, as the latter is frequent in NAFLD patients and MetS, in turn, increases risk for NAFLD. NAFLD has been reported in 22.5% of patients with type 2 diabetes mellitus (DM), in 51.3% of those who are obese, 42.5% of patients with MetS, 39.3% of hypertensive patients and 69.2% of those with hyperlipidemia.…”

Section: Introductionmentioning

confidence: 99%

Non-Alcoholic Fatty Liver Disease in Cuba

2021

MEDICC Review

View full text Add to dashboard Cite

INTRODUCTION With a global adult prevalence of 24%, nonalcoholic fatty liver disease is a global health problem that parallels the worldwide increase of obesity. Its frequency, clinical characteristics and related diseases in Cuba remain unknown.OBJECTIVE Describe the clinical characteristics, comorbidities and personal habits of patients with non-alcoholic fatty liver disease who are being treated in secondary and tertiary health facilities in seven Cuban provinces. METHODS A cross-sectional, multicenter study was carried out in 6601 adults seen at gastroenterology outpatient clinics of nine hospitals in seven Cuban provinces from September 2018 through May 2019. Non-alcoholic fatty liver disease was diagnosed by abdominal ultrasound. The study included 1070 patients who met the diagnostic and study criteria and agreed to participate. Their personal habits and anthropometric and clinical characteristics, comorbidities and other aspects of their medical histories were recorded. RESULTSOf the 1070 participants, 60.7% (649) were women. Participants' average age was 54.5 years and average body mass index was 30.5 kg/m2. A total of 397 (37.1%) were overweight and 574 (53.6%) were obese, 945 (88.3%) led a sedentary lifestyle, 564 (52.7%) had high blood pressure, 406 (37.9%) had lipid disorders and 301 (28.1%) were diabetic. While 484 (45.2%) of patients were asymptomatic, the most frequent clinical signs and symptoms were fatigue (262; 24.5%), dyspepsia (209; 19.5%), abdominal pain (306; 28.5%) and hepatomegaly (189; 17.7%). Liver cirrhosis was present in 37 (3.5%) patients at the time of diagnosis. Family history of type 2 diabetes mellitus and obesity were identifi ed in 391 (36.5%) and 279 (26.1%) of participants, respectively. CONCLUSIONS Prevalence of non-alcoholic fatty liver disease in these Cuban patients coincides with that reported in the Caribbean region, which has high levels of obesity, overweight and sedentary lifestyles. Most were asymptomatic, female or had metabolism-related comorbidities such as high blood pressure, type 2 diabetes mellitus and dyslipidemia.

show abstract

Factores de riesgo de la enfermedad por hígado graso no alcohólico en poblaciones de Latinoamérica: situación actual y perspectivas

Cited by 9 publications

References 15 publications

Correlation of liver fibrosis quantification by morphometry using HepaScan with the analysis of liver biopsies. A pilot study

Correlation of liver fibrosis quantification by morphometry using HepaScan with the analysis of liver biopsies. A pilot study

Hígado graso no alcohólico: certezas e incertidumbres de una epidemia silenciosa

Non-Alcoholic Fatty Liver Disease in Cuba

Contact Info

Product

Resources

About